MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Accelerating the Implementation of Network-based Care for Parkinson’s Disease (ACTION-PD)

    M. Meinders, J. Swillens, A. Antonini, O. Rascol, K. Smilowska, P. Calabresi, M. Steppe, B. Bloem, M. Munneke (Nijmegen, Netherlands)

    Objective: The aim of the study was to evaluate the implementation of network-based care for people living with Parkinson’s disease (PwPD). Background: ParkinsonNet is a…
  • 2026 International Congress

    Neurological Wilson’s disease: another form of tauopathies?

    XP. Wang (Shanghai, China)

    Objective: The authors would hope to identify distribution of Tau protein within the  brain of  Wilson's disease patients by tau-targeted positron emission tomography (PET) tracers Background:…
  • 2026 International Congress

    Efficacy of Novel Antipsychotic Agents on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis of 2,533 Patients

    I. Serag (Mansoura, Egypt)

    Objective: To systematically evaluate and quantitatively synthesize evidence on the effects of novel antipsychotic agents (Clozapine, Olanzapine, Risperidone, and Aripiprazole) on cognitive domains in Parkinson’s…
  • 2026 International Congress

    A Longitudinal Case of Adult-Onset Progressive Ataxia in a Patient with a Pathogenic Variant of IRF2BPL

    S. de Groot, W. Rai (Sioux Falls, USA)

    Objective: To describe the course of a patient with an inherited IRF2BPL variant presenting as adult-onset indolent ataxia and tremor with no prior developmental abnormalities,…
  • 2026 International Congress

    Chronic Vanadium Exposure Promotes Memory Impairment and Aggregation of Alpha-Synuclein, Tau and Amyloid Beta in Mouse Brain

    O. Folarin, F. Olopade, T. Gilbert, A. Ladagu, P. Inês, O. Mustapha, L. Zethan, J. Olopade, T. Outeiro (Ibadan, Nigeria)

    Objective: In this study, we hypothesized that prolonged vanadium exposure may be a potential risk factor for Alzheimer's and Parkinson's diseases. Background: The interaction between…
  • 2026 International Congress

    Does Fgatir Hypointensity Predict Outcomes After Deep Brain Stimulation For Action Tremors

    N. Kahn, S. Abdelaziz1, F. Baig, I. Cociasu, B. Ishihara, S. Ratti, L. Ricciardi, E. Pereira, F. Morgante, M. Hart (London, United Kingdom)

    Objective: To test whether efficacy of Deep Brain Stimulation (DBS) in different action tremor syndromes (Essential tremor, ET, ET-plus, or dystonic tremor as per IPMDS…
  • 2026 International Congress

    The Impact of the Edmond J. Safra Nurse Educator Program at the Parkinson’s Foundation on Nursing Education and Parkinson’s Care

    A. Li Wong (New York, USA)

    Objective: To explore the influence of the Edmond J. Safra Nurse Educator Program on nursing education and its impact on preparing future nurses to care for…
  • 2026 International Congress

    Drivers of Navigated Walking Performance in Aging and Parkinson’s Disease: Insights From Behavioral Clustering, Clinical and Neuroimaging Data

    A. Kvist, L. Bezuidenhout, H. Johansson, U. Ekman, D. Moulaee Conradsson, F. Albrecht, E. Franzén (Stockholm, Sweden)

    Objective: Identify and characterize patterns of navigated walking performance in people with PD (Parkinson’s disease) and healthy adults, by means of data-driven cluster analysis. Background:…
  • 2026 International Congress

    Long-term Safety of Opicapone in Parkinson’s Disease Patients with First Signs of Wearing-off

    JJ. Ferreira, F. Stocchi, A. Antonini, O. Rascol, G. Ebersbach, J. Kulisevsky, N. Pavese, G. Hoglinger, D. Ramos, J-F. Rocha, HC. Brigas, J. Holenz, W. Poewe (Lisboa, Portugal)

    Objective: This post-hoc analysis evaluated opicapone’ s long-term safety and tolerability in Parkinson’s patients with recently diagnosed fluctuations (≤2 years). Background: Opicapone is used to…
  • 2026 International Congress

    Activation of the MT1 Receptor Ameliorates Mitochondrial Dysfunction in MPP+/MPTP-Induced Parkinson’s Disease

    LL. Qi, CF. Liu, F. Wang (Suzhou, China)

    Objective: This study aimed to explore the role of melatonin receptor 1 (MT1) in improving mitochondrial dysfunction in MPP⁺/MPTP-induced PD models and to clarify the…
  • « Previous Page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley